Chikungunya Map: Global Distribution and Risk Areas

Chikungunya virus circulates across tropical and subtropical regions on every inhabited continent, with active or recent transmission documented in more than 110 countries. The risk map has expanded dramatically since the early 2000s, driven by viral mutations that opened new mosquito vectors, international air travel that seeds outbreaks in previously unaffected areas, and climate shifts that push suitable mosquito habitat into temperate zones. What was once considered a regional African and Asian disease now reaches from South America to southern Europe, and projections suggest the map will continue to widen.

Where Chikungunya Circulates Today

The virus was first identified during an outbreak in what is now Tanzania in 1952. For decades it caused periodic epidemics across sub-Saharan Africa and parts of South and Southeast Asia, with outbreaks recorded in South Africa, Zimbabwe, the Democratic Republic of Congo, Nigeria, Thailand, India, and several other countries through the 1960s and 1970s.¹ In India alone, a single outbreak in Chennai in 1964 produced over 400,000 cases. Then the virus seemed to go quiet for years in many regions before roaring back on a global scale starting around 2004.

The modern era of chikungunya began with a massive wave radiating from East Africa through the Indian Ocean islands, India, and Southeast Asia. Since the Indian Ocean lineage emerged in 2005 and 2006, outbreaks and exported cases have been reported across an ever-widening geography.² The virus reached the Caribbean in late 2013, and within a decade roughly 3.7 million suspected and confirmed cases had been reported across 50 countries and territories in the Americas.³ Meanwhile, outbreaks continued cycling through South and Southeast Asia and sub-Saharan Africa. The result is a distribution map that now includes nearly all of the tropics and many subtropical margins.

Three Genotypes, Three Geographic Footprints

Chikungunya is not a single uniform virus. It divides into three major genotypes, each with a distinct geographic origin and spread pattern. The West African genotype originated in Nigeria and has stayed within Africa. The Eastern/Central/South African (ECSA) genotype originated in Tanzania and became the most globally traveled, radiating outward to the Indian Ocean, South Asia, East Asia, and Europe. The Asian genotype originated in Thailand, spread through Southeast Asia and the Pacific islands, and was the lineage that jumped to the Caribbean and then swept the Americas. Of the three, the Asian genotype shows the highest evolutionary rate.⁴

The Indian subcontinent and Southeast Asia have functioned as major hubs for global dispersal, with phylogenetic analyses tracing multiple outbreak introductions in other countries back to strains circulating in those regions.⁵ In China’s Yunnan province, for instance, genomic surveillance of imported and locally transmitted cases has identified at least three circulating genotypes, with the Indian Ocean lineage strains closely related to those in Thailand and the Asian genotype linked to strains from Indonesia.⁶

A Mutation That Redrew the Map

One of the most consequential shifts in chikungunya’s geographic reach traces to a single amino acid change in the virus’s envelope protein. The E1-A226V mutation, identified during the Indian Ocean outbreaks, substantially increased the virus’s ability to infect the Asian tiger mosquito, Aedes albopictus.⁷ Before this adaptation, chikungunya was primarily transmitted by Aedes aegypti, the yellow fever mosquito, which thrives in tropical cities. Ae. albopictus has a wider geographic range, tolerating cooler climates and colonizing suburban and semi-rural habitats across southern Europe, the eastern United States, and East Asia. Adding this mosquito as an efficient vector instantly expanded the areas where outbreaks could take hold.

Follow-up mutations in the E2 and E3 envelope proteins further fine-tuned the virus for Ae. albopictus transmission.⁸ Researchers in Italy compared the strains behind the 2007 outbreak in Emilia Romagna (which carried the E1-A226V mutation) and the 2017 outbreak in Lazio and Calabria (which lacked it). Italian Ae. albopictus mosquitoes showed similar ability to transmit both strains, a finding that suggests the mutation is not the only route to efficient transmission in this species and that the risk to temperate regions is broader than one mutation alone would imply.⁹

The Two Mosquitoes Behind Transmission

Understanding the risk map means understanding the two main vectors. Ae. aegypti dominates in densely urban tropical environments. Ae. albopictus is more adaptable, found in suburban neighborhoods and periurban areas, and has colonized parts of Europe, North America, and temperate Asia where Ae. aegypti is absent. Both species are competent transmitters. In laboratory comparisons using mosquitoes from Indian Ocean islands, transmission rates for chikungunya reached about 62.5% regardless of which species was tested, and geographic origin of the mosquito population did not significantly affect competence.¹⁰

In central Africa, field investigations have shown that Ae. albopictus can be the primary driver of outbreaks even in cities where Ae. aegypti is present. During simultaneous chikungunya and dengue outbreaks in Libreville, Gabon, in 2007, virus was detected only in Ae. albopictus, which vastly outnumbered Ae. aegypti in suburban areas.¹¹ This matters for risk mapping because it means areas with only Ae. albopictus are not necessarily lower risk; the species can sustain large outbreaks on its own.

Beyond these two primary vectors, research has also flagged forest-dwelling mosquito species in the Americas as competent chikungunya transmitters. Lab studies showed that Haemagogus leucocelaenus and Aedes terrens, both common in tropical American forests, could efficiently pick up and transmit the virus. Hg. leucocelaenus transmitted infectious particles as quickly as three days after feeding on an infected host.¹² If chikungunya were to establish a permanent wildlife cycle in New World primates through these forest mosquitoes, eliminating the virus from the region would become far more difficult.

How Climate Shapes and Shifts the Risk Zone

Temperature is a key control knob for chikungunya transmission. The virus needs time to replicate inside the mosquito before it can be passed along in a bite, a process called the extrinsic incubation period. At cooler temperatures, replication slows drastically. Modeling estimates put the minimum incubation time at about 1.7 days at 30°C but about 8.7 days at 18°C, and the window for competent transmission spans roughly 14°C to 32°C, peaking near 26°C.¹³ In practical terms, this means that warm summer months in temperate Europe or the southeastern United States open a seasonal window during which local transmission is possible if an infected traveler introduces the virus.

Lab experiments confirm this temperature sensitivity. At 28°C, multiple Ae. albopictus populations transmitted chikungunya within three days of feeding, while at 20°C, transmission was delayed and less reliable.¹⁴ Risk assessments for Europe have found that temperature conditions already allow viral incubation in areas where Ae. albopictus is established, and that large parts of central Europe not yet colonized by the mosquito would support transmission if the vector arrived.¹⁵

Climate change projections paint a widening picture. Models using multiple warming scenarios project that suitable areas for chikungunya transmission will expand into northeastern North America, central Europe, and East Asia as temperatures rise.¹⁶ Under moderate warming, regions including the southern United States, sub-Saharan Africa, South America, China, and continental Europe face growing suitability.¹⁷ At the most extreme warming trajectories, some currently tropical habitats could actually become less suitable due to thermal stress on mosquitoes, even as the virus gains a foothold in places that were previously too cool.

How Travelers Seed New Outbreaks

One of the reasons the chikungunya map is so dynamic is that a single infected traveler can start a chain of transmission thousands of miles from any endemic zone. People who pick up the virus abroad can carry it home during the viremic phase, get bitten by local Ae. albopictus mosquitoes, and spark clusters or full-blown outbreaks. This exact sequence has already played out multiple times. Infected travelers seeded chikungunya clusters in France and parts of the United States, and caused outbreaks in Italy in both 2007 and 2017.¹⁸

Modeling of a single outbreak in southern Thailand estimated that roughly 125 cases would be exported to international destinations via air travel. China was projected to receive the most, followed by Singapore and Malaysia. About two-thirds of the projected recipient countries had regions where local transmission could potentially follow.¹⁹ Multiply this by the dozens of outbreaks occurring globally in any given year, and it becomes clear why the risk map is not a fixed image but a constantly shifting overlay of endemic zones, importation corridors, and newly vulnerable territories.

What Determines Risk at the Neighborhood Level

Global and regional maps provide the broad strokes, but risk within a city or neighborhood varies block by block. Research in Brazilian cities has uncovered several local factors that predict where cases concentrate. In Salvador, residents living on hillsides had roughly double the odds of past infection compared to those at lower elevations, and odds increased with each additional meter of elevation up to a point. Proximity to standing water also increased risk.²⁰ The hillside effect is thought to relate to the way informal settlements on slopes often have inconsistent water infrastructure, creating ideal mosquito breeding sites in stored water containers.

Socioeconomic conditions add another layer. Municipalities with high-risk clusters for chikungunya in Brazil had lower rates of sewage coverage, piped water, and garbage collection, along with higher deprivation scores.²¹ Modeling of one Brazilian epidemic found that a higher socioeconomic development index was strongly protective early in the outbreak, but this protective effect vanished at the epidemic’s peak, when transmission was so intense that it overwhelmed even better-resourced neighborhoods.²² In other words, infrastructure and income provide some buffer, but during a large epidemic, no neighborhood within a tropical city is truly safe.

Mapping Beyond Occurrence Points

The most useful risk maps go beyond plotting past outbreaks on a globe. Researchers now use ecological niche models that combine mosquito occurrence data, temperature profiles, precipitation, and vegetation indices to predict where transmission could happen even before cases are reported. In Zambia, for example, modeling identified river corridors and lake margins as spatial hotspots, with rainfall and temperature extremes as the strongest predictive variables.²³

A newer approach generates multi-disease suitability maps that overlay the risk zones for chikungunya, dengue, Zika, and yellow fever simultaneously, since all four viruses share the same mosquito vectors. Using a dataset of over 21,000 occurrence points and a nested surveillance model, researchers produced global maps showing where the environmental envelope for these viruses overlaps.²⁴ For public health agencies, this kind of combined mapping is valuable because vector control for one disease effectively reduces transmission risk for all four.

Why Case Counts Understate the Problem

Official case numbers almost certainly undercount chikungunya, sometimes dramatically. In a Brazilian border city, researchers compared cases confirmed by molecular testing with the cases appearing in routine government surveillance data. Among the molecularly confirmed cases, the initial clinical diagnosis was wrong nearly 60% of the time.²⁵ In areas where dengue and Zika also circulate, the three diseases can look nearly identical in the first few days of fever, rash, and body aches, and without lab confirmation clinicians frequently guess wrong. This means the actual geographic footprint of chikungunya is likely broader and more intense than what surveillance maps show.

The chronic burden compounds the problem. A modeling analysis estimated that roughly three-quarters of the disability attributed to chikungunya comes not from the acute fever but from lingering joint pain and fatigue that can persist for months or years.²⁶ These chronic cases rarely show up in outbreak dashboards, so the human impact in affected regions is larger than real-time maps suggest.

Who Faces the Highest Risk in Endemic Areas

Within any affected zone, the risk of severe outcomes is not evenly distributed. A systematic review of clinical outcomes across age groups found that hospitalization and death rates were highest among older adults and young children. Older children tended to recover faster than other groups, while chronic symptoms like persistent joint pain became more common with increasing age.²⁷ In young children and the elderly, symptom patterns are often atypical, with less of the classic joint pain that prompts clinicians to suspect chikungunya, raising the risk of missed diagnoses.

A meta-analysis of mortality risk factors quantified the danger. People aged 60 and older had dramatically elevated odds of dying from chikungunya, and those with diabetes, high blood pressure, or chronic kidney disease also faced substantially higher odds. Male sex and the symptom of vomiting were additional risk markers.²⁸ For travelers and residents of endemic areas, this means that age and existing health conditions matter more than geography alone in determining personal risk.

Vector Control and the Promise of Wolbachia

Because there is still no widely deployed vaccine, the front line of chikungunya prevention remains mosquito control. Traditional approaches (removing standing water, spraying insecticides, using bed nets and repellents) remain the backbone, but newer biological strategies are gaining ground. One of the most promising involves Wolbachia, a naturally occurring bacterium that can be introduced into mosquito populations to block viral replication. In lab experiments, Ae. albopictus mosquitoes carrying a specific Wolbachia strain transmitted chikungunya at drastically reduced rates compared to uninfected mosquitoes.²⁹

A related approach combines sterile insect and incompatible insect techniques. In a field trial in Thailand, releasing sterile male Ae. aegypti mosquitoes over six months reduced the egg hatch rate in treated areas by about 84% and the number of female mosquitoes per household by over 97%.³⁰ Lab assessments of artificially infected Ae. albopictus strains suggest the Wolbachia infections do not harm the mosquitoes’ fitness enough to prevent mass rearing, making scaled deployment feasible.³¹ These techniques do not eliminate mosquitoes from the landscape, but they can suppress populations enough to break transmission chains during outbreaks.

The Wildlife Reservoir Question

In Africa, chikungunya has long been known to circulate among non-human primates in a forest cycle separate from urban outbreaks. Research in Senegal’s Kédougou region found high rates of past infection in young monkeys, indicating active transmission in the forest even in years when no infected mosquitoes were detected in traps. The researchers concluded that monkeys serve as amplification hosts rather than long-term reservoirs, meaning they boost the virus to high enough levels for mosquitoes to pick it up, but they do not maintain it indefinitely on their own.³²

Whether a similar wildlife cycle could establish itself in the Americas remains an open and consequential question. The competence of forest-dwelling mosquito species in the region, combined with large populations of New World primates in tropical forests, means the ingredients are present. If a permanent animal reservoir were to take hold, chikungunya could become impossible to eradicate from the hemisphere, periodically spilling back from wildlife into human populations in a pattern similar to yellow fever in South America. Public health authorities track this possibility closely, but so far no confirmed wildlife cycle has been documented outside Africa.

Vaccines on the Horizon

A live-attenuated chikungunya vaccine (Ixchiq) received approval from the U.S. FDA in late 2023 for adults at increased risk of exposure, making it the first licensed chikungunya vaccine. Broader deployment, however, faces significant hurdles. Decisions on vaccine introduction in endemic countries require solid data on local disease burden and cost-effectiveness, and a sustainable financing mechanism needs to be established to manufacture at scale and distribute equitably to at-risk populations across different geographic settings.³³ For now, the vaccine is most relevant to travelers and laboratory workers in high-income countries, while the populations bearing the largest burden of disease in the tropics largely remain without access. Real-time genomic tracking, integrated vector management, and water-source surveillance continue to be the mainstays of outbreak containment worldwide.³⁴